Compare Charles River Laboratories Intl. Inc (CRL) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Linde PLC — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Linde PLC trades at $481.01 (market cap $222.05B). The key difference: Linde PLC is far larger — about 15.6× Charles River Laboratories Intl. Inc's market cap, and Linde PLC pays a 1.33% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Linde PLC for 88 Days on average.
| CRL | LIN | |
|---|---|---|
Market Cap | $14.23B | $222.05B |
Volume | 1,176,885 | 2,116,440 |
Sector | Health | Basic Materials |
52-Week High | $310.77 | $546.64 |
52-Week Low | $149.93 | $389.38 |
Typical Hold Time | 33 Days | 88 Days |
Enterprise Value | $17.06B | $245.17B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
LIN trades at $481.70, down 1.68% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings of $4.50 per share, beating estimates, and raised the lower end of its 2026 guidance. Revenue growth is steady, with a net income margin of 20.43% in 2025. Analyst consensus is overwhelmingly positive, with a $557.10 price target. Support is seen near $480, while resistance lies at $486.
Outlook remains favorable due to consistent earnings beats and a record $8.1 billion project backlog. Risks include elevated valuation multiples and margin pressures from higher capital expenditures. The stock offers a dividend yield with a $1.60 payment scheduled for September 2026. Investor sentiment is buoyed by AI-related contract wins, though competition and capex increases warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
